202135-70-4 Usage
Description
5-(Piperazin-1-yl)pyrimidine is a chemical compound characterized by the molecular formula C8H10N4. It features a pyrimidine ring with a piperazine group attached at the 5-position, which endows it with a broad spectrum of biological activities. This versatile compound is widely recognized for its potential applications in the pharmaceutical and agrochemical industries, making it a valuable building block in the synthesis of various therapeutic agents.
Uses
Used in Pharmaceutical Industry:
5-(Piperazin-1-yl)pyrimidine is used as a key building block for the synthesis of pharmaceuticals due to its diverse biological activities. It has been studied for its potential as an antiviral, antitumor, and antifungal agent, making it a promising candidate for the development of new drugs to combat various diseases.
Used in Agrochemical Industry:
In the agrochemical sector, 5-(Piperazin-1-yl)pyrimidine is utilized as a fundamental component in the creation of agrochemicals. Its ability to exhibit a range of biological activities positions it as a valuable asset in the development of pesticides and other agricultural chemicals to protect crops and enhance yield.
Used in Neurological Disorder Treatment:
5-(Piperazin-1-yl)pyrimidine is used as a therapeutic agent for the treatment of various neurological disorders. Its potential in this area stems from its demonstrated biological activities, which have been the subject of research aimed at identifying its role in managing such conditions.
Used as a Serotonin Receptor Antagonist:
5-(Piperazin-1-yl)pyrimidine is also used as a serotonin receptor antagonist. This application is significant in the field of psychopharmacology, where modulation of serotonin receptors can have profound effects on mood, anxiety, and other neurological functions, offering new avenues for the treatment of related disorders.
Overall, 5-(Piperazin-1-yl)pyrimidine's multifaceted utility underscores its importance in drug discovery and development, with ongoing research continuing to explore its full potential across different medical and chemical domains.
Check Digit Verification of cas no
The CAS Registry Mumber 202135-70-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,2,1,3 and 5 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 202135-70:
(8*2)+(7*0)+(6*2)+(5*1)+(4*3)+(3*5)+(2*7)+(1*0)=74
74 % 10 = 4
So 202135-70-4 is a valid CAS Registry Number.
InChI:InChI=1/C8H12N4/c1-3-12(4-2-9-1)8-5-10-7-11-6-8/h5-7,9H,1-4H2
202135-70-4Relevant articles and documents
Optimization of 5-substituted thiazolyl ureas and 6-substituted imidazopyridines as potential HIV-1 latency reversing agents
Blackmore, Timothy R.,Jacobson, Jonathan,Jarman, Kate E.,Lewin, Sharon R.,Nguyen, William,Purcell, Damian F.,Sabroux, Helene Jousset,Sleebs, Brad E.
, (2020/04/08)
A persistent latent reservoir of virus in CD4+ T cells is a major barrier to cure HIV. Activating viral transcription in latently infected cells using small molecules is one strategy being explored to eliminate latency. We previously described the use of a FlpIn.FM HEK293 cellular assay to identify and then optimize the 2-acylaminothiazole class to exhibit modest activation of HIV gene expression. Here, we implement two strategies to further improve the activation of viral gene expression and physicochemical properties of this class. Firstly, we explored rigidification of the central oxy-carbon linker with a variety of saturated heterocycles, and secondly, investigated bioisosteric replacement of the 2-acylaminothiazole moiety. The optimization process afforded lead compounds (74 and 91) from the 2-piperazinyl thiazolyl urea and the imidazopyridine class. The lead compounds from each class demonstrate potent activation of HIV gene expression in the FlpIn.FM HEK293 cellular assay (both with LTR EC50s of 80 nM) and in the Jurkat Latency 10.6 cell model (LTR EC50 220 and 320 nM respectively), but consequently activate gene expression non-specifically in the FlpIn.FM HEK293 cellular assay (CMV EC50 70 and 270 nM respectively) manifesting in cellular cytotoxicity. The lead compounds have potential for further development as novel latency reversing agents.
New μ-opioid receptor agonists with piperazine moiety
Komoto,Okada,Sato,Niino,Oka,Sakamoto
, p. 1314 - 1320 (2007/10/03)
New μ-opioid receptor (MOR) agonists containing piperazine and homopiperazine moieties in the structures were synthesized and their affinities to and agonist potencies on MOR were evaluated. Among the synthesized compounds, 4-[4-(2-methoxyphenyl)piperazin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide (20Aa) showed the highest affinity to the human MOR expressed in Chinese hamster ovary (CHO)-K1 cells, and the highest agonist potency on the MOR in isolated guinea-pig ileum preparation.
